Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 single-arm study of tislelizumab in previously treated unresectable or metastatic MSI-H/dMMR solid tumors
CTR20180867Phase 2Active
- Sponsor
- BeOne Medicines
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tislelizumab in Nonhematologic neoplasms, mismatch repair deficient solid tumor, sponsored by BeOne Medicines. Started Sep 2018; status: active.
02
Drugs
tislelizumab
03
Conditions
Nonhematologic neoplasmsmismatch repair deficient solid tumor
Beyond the preview
Go deeper on CTR20180867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180867.